<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1498">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141656</url>
  </required_header>
  <id_info>
    <org_study_id>CPOG-CDPC-01</org_study_id>
    <nct_id>NCT05141656</nct_id>
  </id_info>
  <brief_title>Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center</brief_title>
  <official_title>Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center observational study. The start time for data collection is&#xD;
      August 31, 2019. Patients who have been treated at our institution from August 31, 2019, who&#xD;
      were diagnosed with pancreatic tumors on or before August 31, 2019 (diagnosed in our hospital&#xD;
      or outside hospitals) would all meet the inclusion conditions of the study and be considered&#xD;
      enrollment. Patients' baseline and treatment data will be collected under informed concent.&#xD;
      The combination of medical big data governance and the leading technology of the big data&#xD;
      platform uses real world data to improve the quality and efficiency of pancreatic tumor&#xD;
      diagnosis, treatment and scientific research.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 31, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>5 years</time_frame>
    <description>overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>5 years</time_frame>
    <description>disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>5 years</time_frame>
    <description>progress free survival</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <description>Patients diagnosed as pancreatic tumor will considered to be enrolled regardless of specific pathologic subtypes expect for metastasis of pancreas. Baseline data and treatment information will be collected under fully informed consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention will be considered in this study.</intervention_name>
    <description>No intervention will be considered in this study.</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed as tumor of pancreas will all be considered for enrollment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18, both male and female;&#xD;
&#xD;
          2. Patients with primary pancreatic tumor diagnosed by histology, cytology or imaging;&#xD;
&#xD;
          3. Clinical or pathological staging is locally advanced or metastatic pancreatic tumor&#xD;
             (newly diagnosed or after surgery and other treatments);&#xD;
&#xD;
          4. You can accept or have not received surgery, chemotherapy, radiotherapy, local&#xD;
             treatment or traditional Chinese medicine for tumors;&#xD;
&#xD;
          5. The subject voluntarily joined the study and signed an informed consent form&#xD;
             voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Pancreatic tumors are evaluated as metastatic lesions, not primary tumors of the&#xD;
        pancreas.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RenJiH</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 20, 2021</last_update_submitted>
  <last_update_submitted_qc>November 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

